Deze pagina is automatisch vertaald en de nauwkeurigheid van de vertaling kan niet worden gegarandeerd. Raadpleeg de Engelse versie voor een brontekst.

Een studie van GSK5458514 alleen toegediend of in combinatie met andere anti-kankermiddelen bij deelnemers met uitgestrekte kanker

1 oktober 2026 bijgewerkt door: GlaxoSmithKline

Een fase 1/2 eerste-in-humaan, open-label, multicenter, dosis escalatie en expansiestudie van GSK5458514 PSMA richt zich alleen op T-cel en in combinatie met andere anti-kankermiddelen bij volwassen deelnemers met metastatische castratie-resistente prostaatkanker (MCRPC) (MCRPC) (MCRPC) (MCRPC) (MCRPC) (MCRPC) (MCRPC) (MCRPC) (MCRPC) (MCRPC) (MCRPC) (MCRPC)

The goal of the study is to evaluate how safe and how well the body handles GSK5458514 when administered in participants with prostate cancer. The study will be conducted in two parts - Part 1 (dose escalation phase) and Part 2 (dose expansion phase).

Studie Overzicht

Toestand

Werving

Conditie

Interventie / Behandeling

Studietype

Ingrijpend

Inschrijving (Geschat)

85

Fase

  • Fase 2
  • Fase 1

Contacten en locaties

In dit gedeelte vindt u de contactgegevens van degenen die het onderzoek uitvoeren en informatie over waar dit onderzoek wordt uitgevoerd.

Studiecontact

Studie Contact Back-up

Studie Locaties

    • Ontario
      • Toronto, Ontario, Canada, M4N 3M5
        • Werving
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Hoofdonderzoeker:
          • Daniel Khalaf
    • Quebec
      • Montreal, Quebec, Canada, H4A 3J1
        • Werving
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Hoofdonderzoeker:
          • Ramy Saleh
      • Montreal, Quebec, Canada, H3T 1E2
        • Werving
        • GSK Investigational Site
        • Hoofdonderzoeker:
          • April Rose
        • Contact:
        • Contact:
      • Lyon, Frankrijk, 69373
        • Werving
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Hoofdonderzoeker:
          • Armelle Vinceneux
      • Villejuif, Frankrijk, 94805
        • Werving
        • GSK Investigational Site
        • Hoofdonderzoeker:
          • Yohann Loriot
        • Contact:
        • Contact:
      • Kanagawa, Japan, 232-0024
        • Werving
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Hoofdonderzoeker:
          • Takashi Kawahara
      • Tokyo, Japan, 104-0045
        • Werving
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Hoofdonderzoeker:
          • Tatsunori Shimoi
      • Tokyo, Japan, 135-8550
        • Werving
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Hoofdonderzoeker:
          • Yuji Miura
      • Badajoz, Spanje, 06080
        • Werving
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Hoofdonderzoeker:
          • Marta González Cordero
      • Barcelona, Spanje, 08023
        • Werving
        • GSK Investigational Site
        • Hoofdonderzoeker:
          • Tatiana Hernandez
        • Contact:
        • Contact:
      • Madrid, Spanje, 28040
        • Werving
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Hoofdonderzoeker:
          • Bernard Doger
      • Madrid, Spanje, 28050
        • Werving
        • GSK Investigational Site
        • Hoofdonderzoeker:
          • Emiliano Calvo Aller
        • Contact:
        • Contact:
      • Málaga, Spanje, 29010
        • Werving
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Hoofdonderzoeker:
          • Lucia Oliva Fernandez
      • Pozuelo de AlarcOn Madr, Spanje, 28223
        • Werving
        • GSK Investigational Site
        • Hoofdonderzoeker:
          • VALENTINA BONI
        • Contact:
        • Contact:
    • Arizona
      • Phoenix, Arizona, Verenigde Staten, 85054
        • Werving
        • GSK Investigational Site
        • Contact:
        • Hoofdonderzoeker:
          • Yousef Zakharia
        • Contact:
    • Colorado
      • Denver, Colorado, Verenigde Staten, 80218-1234
        • Werving
        • GSK Investigational Site
        • Hoofdonderzoeker:
          • Gerald Falchook
        • Contact:
        • Contact:
    • Connecticut
      • New Haven, Connecticut, Verenigde Staten, 06510
        • Werving
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Hoofdonderzoeker:
          • Daniel Petrylak
    • Minnesota
      • Rochester, Minnesota, Verenigde Staten, 55905
        • Werving
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Hoofdonderzoeker:
          • Dan Childs
    • New Jersey
      • East Brunswick, New Jersey, Verenigde Staten, 08816
        • Werving
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Hoofdonderzoeker:
          • Bruno Fang
    • Tennessee
      • Nashville, Tennessee, Verenigde Staten, 37203
        • Werving
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Hoofdonderzoeker:
          • Benjamin Garmezy

Deelname Criteria

Onderzoekers zoeken naar mensen die aan een bepaalde beschrijving voldoen, de zogenaamde geschiktheidscriteria. Enkele voorbeelden van deze criteria zijn iemands algemene gezondheidstoestand of eerdere behandelingen.

Geschiktheidscriteria

Leeftijden die in aanmerking komen voor studie

18 jaar en ouder (Volwassen, Oudere volwassene)

Accepteert gezonde vrijwilligers

Nee

Geslachten die in aanmerking komen voor studie

Mannelijk

Beschrijving

Inclusion Criteria:

  • Provide signed informed consent. Participants must be capable of providing informed consent, which includes compliance with the requirements and restrictions listed in the Informed consent form (ICF) and in this protocol.
  • Male participants greater than equal to (>=)18 years of age (or the legal age of consent in the jurisdiction in which the study is taking place) at the time of signing the ICF.

Male participants are eligible to participate if they agree to the following during the study intervention period and for at least 195 days, after the last dose of study intervention:

Refrain from donating sperm

PLUS either:

Be abstinent from heterosexual intercourse as their preferred and usual lifestyle (abstinent on a long-term and persistent basis) and agree to remain abstinent.

OR

Must agree to use contraception as detailed below:

Agree to use a male condom and should also be advised of the benefit for a female partner to use a highly effective method of contraception as a condom may break or leak when having sexual intercourse with a woman of childbearing potential (WOCBP) who is not currently pregnant.

  • Participants with mCRPC:

    • Histologically or cytologically confirmed adenocarcinoma of the prostate
    • Metastatic disease diagnosed either by radiologic imaging (Positron emission tomography [PET]- Computed tomography [CT]) and/or regular CT and/or Magnetic resonance imaging (MRI) and/or bone scan
    • Castration-resistant status as per PCWG3 criteria
  • Has prior novel anti-androgen receptor therapy failure and had treatment failure with 1-2 taxane-based chemotherapy regimens including for metastatic hormone sensitive prostate cancer.

  • Has (1) at least 1 soft tissue target lesion per Prostate Cancer Working Group 3 (PCWG3)-modified Response Evaluation Criteria in Solid Tumors, version 1.1 (RECIST 1.1) OR (2) if Non-Target soft tissue disease only per PCWG3-modified RECIST 1.1, may be included if a rise in Prostate-specific antigen (PSA) on 2 successive determinations at least 1 week apart (the most recent screening measurement must have been >= 2 nanograms per milliliter (ng/mL) with testosterone levels <50 nanograms per deciliter (ng/dL), OR (3) bone disease defined by PCWG3 (2 or more lesions on bone scan at screening), as determined by the investigator.

  • Documented disease progression on most recent systemic anti-cancer therapy defined by fulfilling at least 1 of the PCWG3 criteria

  • Have serum testosterone <50 ng/dL (<1.7 nM). Patients must have undergone bilateral orchiectomy or be on continuous androgen-deprivation therapy with a Gonadotropin-releasing hormone (GnRH) agonist or antagonist; this therapy must have been initiated at least 4 weeks prior to randomization and treatment must be continued throughout the study.

  • Eastern Cooperative Oncology Group (ECOG) performance status <=1, with no deterioration in the 2 weeks before step-up treatment period Day 1.

  • Have supplied tumor tissue from a newly obtained biopsy or archival tumor tissue for retrospective detection of Prostate-specific membrane antigen (PSMA) expression and other biomarker analysis. Tissue from a newly obtained biopsy is preferred. If a newly obtained biopsy is not feasible, archival tumor tissue preferably taken after the completion of the participant's last line of therapy prior to the first dose of study drug is acceptable.

  • Participants must have adequate organ function

Exclusion criteria:

  • Pathological finding consistent with small cell, neuroendocrine carcinoma of the prostate or any histology different from adenocarcinoma.

  • History of central nervous system (CNS) metastases or leptomeningeal disease.

  • Diagnosis of invasive malignancy or history of invasive malignancy other than the disease under study within the last 5 years, except as noted below:

    • History of an invasive malignancy for which the participant was definitively treated, and in which the participant has been disease free for at least 2 years, and which, in the opinion of the principal investigator and medical monitor, is not expected to affect the evaluation of the effects of the study intervention on the currently targeted disease under study
    • Curatively treated basal cell carcinoma of the skin, superficial bladder cancer, squamous cell carcinoma of the skin, and/or in situ breast cancer may be enrolled
  • Has ongoing adverse reaction(s) from prior therapy that have not recovered to <=Grade 1 or to the baseline status preceding prior therapy, excluding [e.g., alopecia, hearing loss, vitiligo, endocrinopathy managed with replacement therapy, and Grade 2 neuropathy], or that the investigator, with the agreement of the sponsor, considers to be not clinically relevant for the tolerability of study intervention in the current clinical study.

  • Confirmed history or recurrent autoimmune disease that has required systemic treatments in the 2 years prior to screening. Participants with prior history of autoimmune disease must be discussed with the medical monitor. Replacement therapy is not considered a form of systemic therapy (e.g., thyroid hormone for autoimmune thyroiditis or insulin is not exclusionary).

  • Has evidence of interstitial lung disease, non-infectious pneumonitis, and/or a history of interstitial lung disease, non-infectious pneumonitis that required steroid.

  • Has received any anti-cancer therapy or prior systemic biologic therapy, including immunotherapy within 30 days prior to first dose of study intervention.

  • Prior PSMA radionuclide therapy within 2 months prior to GSK5458514 unless participant received <2 cycles.

  • Prior PSMA-Chimeric antigen receptor T cell therapy (CAR-T) cell therapy and PSMA (T cell engager) TCE/ Bispecific T cell engagers (BiTE) or other prostate Tumor-associated antigens (TAA) specific T cell engager (TCE).

  • Has any history of prior allogenic or autologous bone marrow transplant or other solid organ transplant.

  • Has known sensitivity to study intervention components or excipients or other allergy that, in the opinion of the investigator or medical monitor, contraindicates participation in the study.

  • History of severe neurological or psychiatric disorder, including epilepsy, dementia, or major depression deemed to interfere with study assessments.

  • Has had any major surgery (such as craniotomy, thoracotomy, or laparotomy, etc.) within 4 weeks prior to first dose of study intervention.

  • Serious infections within 4 weeks prior to the first dose, including but not limited to infectious complications, bacteremia, severe pneumonia treated with IV antibiotics for >=2 weeks; active infections with therapeutic IV antibiotics within 2 weeks prior to the first dose or oral antibiotics within 1 week prior to the first dose. Participants who are receiving or have received prophylactic antibiotics (e.g., prophylaxis against urinary infections) are allowed.

Liver safety exclusion criteria:

  • Has an Alanine aminotransferase (ALT) value >2.5x upper limit of normal (ULN) or >5x ULN if documented history of liver metastases.
  • Has a total bilirubin value >1.5x ULN.
  • Has cirrhosis or current unstable liver or biliary disease per investigator assessment defined by the presence of ascites, encephalopathy, coagulopathy, hypoalbuminemia, esophageal/gastric varices, or persistent jaundice.
  • Has documented presence of Hepatitis B surface antigen (HBsAg), at screening or within 3 months prior to the first dose of study intervention.
  • Has a positive Hepatitis C virus (HCV) antibody test result at screening or within 3 months prior to Cycle 1 Day 1 unless the participant can meet the following criteria: NOTE: Participants with a positive HCV antibody test result due to prior resolved disease can be enrolled if a confirmatory negative HCV RNA test is obtained and the participant otherwise meets entry criteria
  • Has a positive HCV ribonucleic acid (RNA) test result at screening or within 3 months prior to the first dose of study intervention. NOTE: The HCV RNA test is optional, and participants with a negative HCV antibody test are not required to undergo HCV RNA testing as well.
  • Is unable to adhere to the protocol defined SoA, including requirements for the Follow-up Period of the study, study procedures, restrictions, and requirements as determined by the investigator.

Studie plan

Dit gedeelte bevat details van het studieplan, inclusief hoe de studie is opgezet en wat de studie meet.

Hoe is de studie opgezet?

Ontwerpdetails

  • Primair doel: Behandeling
  • Toewijzing: Gerandomiseerd
  • Interventioneel model: Sequentiële toewijzing
  • Masker: Geen (open label)

Wapens en interventies

Deelnemersgroep / Arm
Interventie / Behandeling
Experimenteel: Deel 1: Dosis escalatie van GSK5458514 monotherapie

GSK5458514 will be administered.

Experimenteel: Deel 2: Dosisuitbreiding van GSK5458514 Monotherapie

GSK5458514 will be administered.

Wat meet het onderzoek?

Primaire uitkomstmaten

Uitkomstmaat
Tijdsspanne
Aantal deelnemers met dosisbeperkende toxiciteiten (DLT's) tijdens de DLT -observatieperiode
Tijdsspanne: Tot 28 dagen
Tot 28 dagen
Aantal deelnemers met bijwerkingen (AES), ernstige bijwerkingen (SAES), door ernst
Tijdsspanne: Tot ongeveer 29 maanden
Tot ongeveer 29 maanden
Aantal deelnemers met AE's die leidt tot dosisaanpassingen
Tijdsspanne: Tot ongeveer 29 maanden
Tot ongeveer 29 maanden

Secundaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Gebied onder concentratie van 0 tot T (AUC 0-T) van GSK5458514
Tijdsspanne: Tot ongeveer 32 maanden
Tot ongeveer 32 maanden
Maximale concentratie (Cmax) van GSK5458514
Tijdsspanne: Tot ongeveer 32 maanden
Tot ongeveer 32 maanden
Tijd om maximale concentratie (TMAX) van GSK5458514 te bereiken
Tijdsspanne: Tot ongeveer 32 maanden
Tot ongeveer 32 maanden
Aantal deelnemers met anti-drug antilichamen (ADA) tegen GSK5458514
Tijdsspanne: Tot ongeveer 32 maanden
Tot ongeveer 32 maanden
Titers van ADA tegen GSK5458514
Tijdsspanne: Tot ongeveer 32 maanden
Tot ongeveer 32 maanden
Prostate-specific Antigen Decrease From Baseline >=50% (PSA50) Response Rate
Tijdsspanne: Up to approximately 32 months

PSA50 response rate is defined as percentage of participants with a decrease of >=50% in the PSA concentration from the baseline PSA value, confirmed at least 3 weeks later.

Up to approximately 32 months
Objective Response Rate (ORR)
Tijdsspanne: Up to approximately 32 months

ORR is defined as the percentage of participants in the ORR Evaluable set who have a best overall response (BOR) of confirmed complete response (CR) or partial response (PR) per prostate cancer working group 3 (PCWG3) guidelines as assessed by investigator.

Up to approximately 32 months

Medewerkers en onderzoekers

Hier vindt u mensen en organisaties die betrokken zijn bij dit onderzoek.

Sponsor

Onderzoekers

  • Studie directeur: GSK Clinical Trials, GlaxoSmithKline

Studie record data

Deze datums volgen de voortgang van het onderzoeksdossier en de samenvatting van de ingediende resultaten bij ClinicalTrials.gov. Studieverslagen en gerapporteerde resultaten worden beoordeeld door de National Library of Medicine (NLM) om er zeker van te zijn dat ze voldoen aan specifieke kwaliteitscontrolenormen voordat ze op de openbare website worden geplaatst.

Bestudeer belangrijke data

Studie start (Werkelijk)

12 juni 2025

Primaire voltooiing (Geschat)

26 oktober 2027

Studie voltooiing (Geschat)

9 augustus 2028

Studieregistratiedata

Eerst ingediend

22 mei 2025

Eerst ingediend dat voldeed aan de QC-criteria

22 mei 2025

Eerst geplaatst (Werkelijk)

25 mei 2025

Updates van studierecords

Laatste update geplaatst (Werkelijk)

5 oktober 2026

Laatste update ingediend die voldeed aan QC-criteria

1 oktober 2026

Laatst geverifieerd

1 september 2026

Meer informatie

Termen gerelateerd aan deze studie

Andere studie-ID-nummers

  • 223050
  • 2025-521581-10-00 (Ctis)
  • 2025 (Subsidie/contract van de Amerikaanse NIH)

Plan Individuele Deelnemersgegevens (IPD)

Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?

JA

Beschrijving IPD-plan

Study Sponsor will assess requests from qualified researchers for anonymized individual patient-level data and related study documents. Data sharing is subject to certain criteria, conditions, and exceptions. For further information, refer to https://www.gsk-studyregister.com/gsk-patient-level-data-sharing-july2025.pdf

IPD-tijdsbestek voor delen

Anonymized IPD will be made available within 6 months of publication of primary, key secondary and safety results for studies in product with approved indication(s) or terminated asset(s) across all indications.

IPD-toegangscriteria voor delen

Anonymized IPD is shared with researchers whose proposals are approved by an Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months, but an extension may be granted, when justified, for up to 6 months.

IPD delen Ondersteunend informatietype

  • LEERPROTOCOOL
  • SAP
  • ICF
  • MVO

Informatie over medicijnen en apparaten, studiedocumenten

Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel

Ja

Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct

Nee

Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .